SEATTLE, WA - Today’s standard vaccine development approach leaves the nation vulnerable to an ever-growing number of infectious disease threats. We depend on an unduly time consuming and expensive vaccine development process that is largely siloed and driven by potential profit for big pharma. And while the domestic response to the COVID-19 pandemic demonstrated our ability to create a vaccine that prevents severe infection, it highlighted critical gaps in our ability to provide sustainable protection against emerging infectious disease threats. AAHI, with its partners and collaborators, proposes establishment of a collaborative network to bridge those gaps.
On Thursday, April 4, AAHI’s Chief Strategy Officer and General Counsel, Candice Decaire, hosts Vaccine Innovation: The Path to Global Health Resilience – a panel discussion about the strategic partnerships required to build reliable vaccine infrastructure for domestic readiness and global protection.
AAHI proposes establishment of a collaborative network of allied centers of excellence to innovate cutting edge vaccines that are practically accessible – built with sustainably sourced raw materials, designed to be stable for storage and distribution, and developed to be ready to manufacture at scale, for readiness to meet urgent public health threats. The proposed Network of Centers of Excellence for Vaccine Innovation and Development would connect non-profit, for-profit, and academic organizations who have complementary areas of expertise and relationships with external manufacturing partners, for a clear path from design and development to testing and large-scale production of much needed vaccines. The Centers would work together, leveraging the most recent scientific and process advancements to arm our nation with a library of vaccine candidates that are broadly effective, durable, accessible, and poised and ready to deploy against emerging threats.
The discussion will include leading experts in vaccine innovation, development, and strategy and will focus on pragmatic innovation to ensure availability and accessibility of vaccines, including cost-effective use of sustainable raw materials; formulations that are stable for long shelf life and easy, economical distribution; and products designed for streamlined manufacture. The group will also talk about the importance of “baking in” technology transfer to manufacturing partners during the development process, leveraging existing commercial partnerships for early transfer of manufacturing know-how to enable “warp speed” response to emerging infectious threats.
For more information, see our recent letter to Congress, explaining how the establishment of a network of Centers of Excellence would fill critical gaps in our vaccine development infrastructure and complements existing government initiatives, such as Project NextGen and ARPA-H’s APECx program.